구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CAR T-Cell Infusion |
Overview Company | PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
Overview Modality | CGT |
Overview Target | Leukemia |
Overview Indication | Relapsed Acute Lymphoblastic Leukemia (ALL) |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Real-world use of polatuzumab vedotin combined with bendamustine and rituximab for patients with relapsed or refractory large B-cell lymphoma.. Polatuzumab vedotin combined with bendamustine and rituximab (Pola-BR) is a treatment option for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), particularly as bridging therapy before chimeric antigen receptor (CAR) T-cell infusion. However… |
Toxicology CRS | Reported |
Clinical Safety signal | Real-world use of polatuzumab vedotin combined with bendamustine and rituximab for patients with relapsed or refractory large B-cell lymphoma.. Polatuzumab vedotin combined with bendamustine and rituximab (Pola-BR) is a treatment option for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), particularly as bridging therapy before chimeric antigen receptor (CAR) T-cell infusion. However… |
Clinical Selected reported efficacy | ORR 67% |
Clinical Reported ORR | 67% |
Clinical Result source | ClinicalTrials.gov NCT03704298 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03704298 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CAR T-Cell Infusion |
Overview Company | PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
Overview Modality | CGT |
Overview Target | Leukemia |
Overview Indication | Relapsed Acute Lymphoblastic Leukemia (ALL) |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Real-world use of polatuzumab vedotin combined with bendamustine and rituximab for patients with relapsed or refractory large B-cell lymphoma.. Polatuzumab vedotin combined with bendamustine and rituximab (Pola-BR) is a treatment option for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), particularly as bridging therapy before chimeric antigen receptor (CAR) T-cell infusion. However… |
Toxicology CRS | Reported |
Clinical Safety signal | Real-world use of polatuzumab vedotin combined with bendamustine and rituximab for patients with relapsed or refractory large B-cell lymphoma.. Polatuzumab vedotin combined with bendamustine and rituximab (Pola-BR) is a treatment option for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), particularly as bridging therapy before chimeric antigen receptor (CAR) T-cell infusion. However… |
Clinical Selected reported efficacy | ORR 67% |
Clinical Reported ORR | 67% |
Clinical Result source | ClinicalTrials.gov NCT03704298 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03704298 |
추천 비교
추천 비교